Loading organizations...
IbisVision develops an online platform providing remote eyecare solutions, enabling virtual vision testing. Core products IBISengage and IBISrecheck facilitate online refraction, clinician-led exams, and self-guided prescription verification. The platform integrates remote triage, video consultations, and appointment scheduling, delivering accessible digital eyecare and extending optometric services via telehealth.
Founded in 2014 by Dr. Blair Donaldson, a former eye surgeon, IbisVision emerged from his insight into modernizing eyecare. He recognized the need to empower professionals to efficiently reach more patients, envisioning a system combining clinical rigor with technology to overcome geographical barriers and enhance access to vision services.
Eyecare professionals and optometry practices primarily utilize IbisVision's solutions, expanding services through telemedicine. They employ the company’s tools for remote assessments and flexible patient care management. IbisVision envisions a future where high-quality eyecare is universally accessible, enabling individuals to receive professional vision services conveniently, irrespective of location.
IbisVision has raised $6.0M across 1 funding round.
IbisVision has raised $6.0M in total across 1 funding round.
IbisVision has raised $6.0M in total across 1 funding round.
IbisVision's investors include Deepbridge Capital, Richard Thompson.
IbisVision has raised $6.0M across 1 funding round. Most recently, it raised $6.0M Series U in May 2023.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| May 1, 2023 | $6M Series U | — | Deepbridge Capital, Richard Thompson | Announced |
IbisVision is a UK-based technology company founded in 2014 that develops a cloud-based vision testing platform for eyecare professionals and patients.[1] It offers remote tools like online vision tests (visual acuity, color, visual field, Amsler), refractions, and self-guided prescription checks via products such as IbisEngage (clinician-led) and Ibis Re-Check (patient self-serve), serving the optical industry to connect optometrists and patients efficiently.[1][2][3] The platform solves clinician shortages and access issues by enabling remote exams, reducing in-office time, and optimizing resource distribution, with $5.66M raised in Series A funding and recent U.S. market expansion.[1]
Growth momentum includes platform expansions from single tests to comprehensive suites, strategic partnerships with eyecare operators, and launches like Ibis Re-Check at Vision Expo East, positioning it in the digital health space with a Mosaic Score up +20 points recently.[1]
IbisVision emerged in 2014 in Glasgow, U.K., addressing growing demand for eyecare amid clinician shortages by pioneering internet-based eye tests.[1][3] While specific founders are not detailed in available sources, CEO Mark Roger has led its evolution, emphasizing flexible, location-independent testing to mirror models like Uber for clinical resources.[3] Early traction built on a single-test platform, expanding to multiple exams on a secure, intuitive SaaS model with database and communications tools, gaining interest from eyecare operators and achieving Series A funding ($5.66M, last raised about a year ago).[1][2][3][5]
Pivotal moments include widening strategy to link remote clinicians globally, boosting doctor availability, and recent U.S. entry with validated remote refraction systems.[1][3]
IbisVision rides the digital health and telehealth wave in eyecare, capitalizing on post-pandemic remote care demand, clinician shortages, and rising eye health needs from aging populations and screen time.[1][3] Timing aligns with regulatory progress for remote refractions (undergoing U.S. validation) and market forces like flexible work models, enabling global talent pooling akin to gig economy platforms.[1][3] It influences the ecosystem by partnering with optical providers, reducing inefficiencies, and pushing adoption of internet-based diagnostics in a sector slow to digitize, as seen in its Expert Collection inclusion for digital health.[1][3]
IbisVision is poised for scaled U.S. growth with Re-Check and Engage, leveraging its validated tech to capture tele-eyecare market share amid clinician gaps.[1] Trends like AI-enhanced diagnostics, global telehealth expansion, and personalized eye care will shape its path, potentially amplifying influence through more operator integrations and feature expansions. As a Series A player with positive momentum, it could redefine accessible vision testing, efficiently linking pros and patients in a resource-strapped landscape.[1][3]
